Hepatocellular Carcinoma in Patients Suffering from Chronic Hepatitis B versus Co-Infection of Hepatitis B and D Virus by Hussain Khokhar, Riaz et al.
                            203 JIMDC  2017  203 
Open Access 
Ful l  Length  Art ic l e  
 
 Hepatocellular Carcinoma in Patients Suffering from Chronic 
Hepatitis B versus Co-Infection of Hepatitis B and D Virus 
Riaz Hussain Khokhar 1, Anwar Ali Jamali 2, Shohabudin Rind 3 
1 Postgraduate Department, Gastrointestinal & liver Diseases, Isra University Hospital at Hyderabad 
2 Assistant Professor, Department of Medicine, Peoples University of Medical and Health Sciences Nawabshah, Sind 
3 Postgraduate Department, Gastrointestinal & liver Diseases of Isra University Hospital at Hyderabad  
 
A B S T R A C T  
Objective: To determine the frequency of hepatic cancer in subjects suffering from chronic liver disease due to hepatitis 
B versus hepatitis B with co-infection of viral hepatitis D. 
Patients and Methods: This cross-sectional study was carried out in the Department of Medicine (Hepatology & 
Gastroenterology) at Isra University Hospital, Hyderabad Sindh, from March 2015 to February 2016. Both male and 
female patients, from 20-70 years of age either suffering from viral Hepatitis B alone or co-infected with viral hepatitis D 
were included in our research. Individuals having co-infection of Human Immunodeficiency virus, Viral hepatitis C, 
Wilson's disease, Hepatitis due to auto-immune diseases, alcoholic fatty liver disease, haemochromatosis, pregnant 
women and those patients who refused to give consent were excluded from study. 
Results: Out of total 200 patients, 142(71%) were males while 58(29) were females. Mean age was 52.83+15.6 years. 
Total 173(86.5%) patients were suffering from viral hepatitis B alone, while 27(13.5%) were infected by co-infection of 
Viral hepatitis B and D. Total frequency of hepatocellular carcinoma was 45(22.5%) in all cases. HCC was more frequent 
(33.34%) in patients with co-infection of chronic hepatitis B and D, as compared to only chronic hepatitis B patients 
(20.80%) but the difference was non-significant (p-value 0.14). 
Conclusion: Hepatocellular carcinoma was more frequent amongst patients co-infected with viral hepatitis D as 
compared to alone infection of hepatitis B virus. 
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I n t r o d u c t i o n  
 
Hepatocellular carcinoma (HCC) is the commonest 
primary hepatic malignancy. It is also the leading cause of 
malignancy related mortality throughout the world. In the 
United States it is the ninth leading cause of mortality.1 
According to recent data, the rate of HCC is still rising 
globally, although it is variable throughout the world. 
Chronic viral hepatitis can lead to cirrhosis and HCC. 
Hepatitis B, C and D infections are the commonest 
reasons of chronic hepatitis worldwide. Hepatitis B virus is 
the double-stranded circular DNA and having 8 genotypes 
“A to H”. Many epidemiological studies showed that 
hepatitis B infection is responsible for significant 
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hepatocarcinogenicity.1,2 Hepatitis B virus carriers have 
10%–25% lifetime risk of HCC development. Unlike other 
reasons of hepatitis severity, hepatitis B virus is the 
unique and may develop HCC without cirrhotic evidence.3  
Persistent replication of hepatitis D virus and inflammation 
of liver may cause cirrhosis and development of 
hepatocellular carcinoma, while active replications of the 
both hepatitis B virus and hepatitis D virus may be 
responsible for high progression in disease, which leads 
to early liver cirrhosis and hepatic malignancy.4 Several 
epidemiological studies controversially showed different 
role of hepatitis D virus infection in the rising HCC risk. 
Many previously published studies did not found elevated 
rates of HCC in cases having hepatitis D co-infection, but 
in recent literature, it is mentioned that co-infection may 
increase the tumor incidence.4 Risk of the hepatocellular 
carcinoma should be reassessed according to the 
alteration of the natural history of hepatitis D chronic 
disease. However, burden of hepatitis D virus has 
decreased in several countries of the Western world, on 
other hand it is still prevalent still other countries, 
particularly in Asia Pacific Region.5 Association of HCC 
with co-infection of hepatitis D virus and hepatitis B virus 
or with hepatitis B viral infection alone, is still unclear. As 
in many studies it is reported that the development 
hepatocellular carcinoma itself is the complex process 
concerning cumulative gain and the loss of functions and 
mutations affecting tumor suppressor and oncogenic 
products.6,7 It has been reported that hepatitis B virus is 
more responsible for development of hepatocellular 
carcinoma, and hepatitis D virus seems to exert 
epigenetic control over HBV transcription and replication. 
A possible explanation may be that p24 and p27 both 
repress HBV enhancers, pIIE1 and PIIE2 inhibit 
replication, thus accounting for the low serum levels of 
HBV DNA in co-infected patients.8 On other hand, 
Pakistan have recognized a huge difference in the 
occurrence and sharing of HCC between population, who 
are suffering from viral Hepatitis B virus alone and viral 
hepatitis B co-infected with viral hepatitis D in different 
areas.9 The purpose of our study was to determine the 
frequency of HCC in subjects suffering from viral hepatitis 
B alone versus viral hepatitis B co-infected with viral 
hepatitis D virus. 
P a t i e n t s  a n d  M e t h o d s  
This cross-sectional research study was carried out in the 
Department of Medicine (Hepatology & Gastroenterology) 
Isra University Hospital, Hyderabad Sindh from March 
2015 to February 2016. Informed written consent was 
taken from patients or their relatives. Both male and 
female patients of chronic liver disease, either suffering 
from viral Hepatitis B alone or co-infected with viral 
hepatitis D, from 20-70 years of age were included in our 
research. Individuals having age less than 20 years or 
more than 70 years, Co-infection with Human 
Immunodeficiency Virus, viral hepatitis C, Wilson's 
disease, hepatitis due to auto-immune diseases, alcoholic 
fatty liver disease, haemochromatosis, pregnant women 
and those patients who refused to give consent were 
excluded from study.  Complete clinical examination of all 
patients was carried out. All the patients were divided in 
two groups. Group 1 included chronic HBV mono-infection 
patients and group 2 comprised of patients having co-
infection of chronic HBV and HDV. Viral hepatitis B was 
diagnosed on the basis of HBsAg positive on enzymatic 
assays analysis through ELISA. Viral hepatitis D was 
diagnosed in HBsAg positive cases on the basis of 
hepatitis D Virus antibodies on ELISA. The diagnosis of 
hepatocellular carcinoma was suggested in those patients 
who had the clinical features suggestive of hepatocellular 
carcinoma which was further confirmed by tri-phasic 
contrast enhanced CT scan / magnetic resonance 
imaging abdomen, typically showing hyper vascular solid 
hepatic mass with support of high levels (>100 ng/ml) of 
alpha-fetoprotein. Socioeconomic status according to 
monthly income was defined as upper >50,000 
rupees/month, Middle 15,000- 49,000 rupees/month and 
lower <15,000 rupees/month. All data was recorded in the 
pre design performa. Data were entered and analyzed in 
SPSS 16. Mean and standard deviation (SD) were 
calculated for quantitative variables. Frequency and 
percentage were calculated for qualitative variables. Chi-
square test was applied to compare the frequency of HCC 
in HBV mono infection versus HBV+HDV co-infection. p-
value less the 0.05 was considered as statistically 
significant.  
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R e s u l t s  
Out of total 200 patients, 142(71%) were male while 58 
(29%) were females. Mean age of subjects was 
52.83+15.6 years (range was 20-70 years). Most of our 
patients (67%) belonged to middle age group.  Regarding 
the education level, out of 200 subjects 115(57.5%) were 
un-educated. Majority of subjects (56.5%) in our study 
belonged to lower economic class (Table1). 
Among these subjects, 173 were suffering from viral 
hepatitis B alone while 27 subjects were diagnosed to 
have viral hepatitis B and D co-infection (Figure 1). 
 
Figure 1: Patient’s distribution according to HBV and 
HBV+HDV Co-infection (n=200). 
Out of all study participants, 45 were diagnosed with HCC 
and 155 were without hepatocellular carcinoma. Thus, 
total HCC frequency was 22.5% (Figure 2). 
 
 
Figure 2: Patient’s distribution according to 
frequency of HCC (n=200). 
Ultrasound abdomen revealed that 127(63.5%) subjects 
had evidence of chronic liver disease without 
decompensation and remaining 73(36.5%) subjects were 
present with decompensation indicated by ascites, dilated 
portal vein, splenomegaly and malignant change / growth 
/mass. These suspected cases of HCC were stepped up 
for alpha-feto protein level, CT-scan abdomen. After 
performing these investigations, 45(22.5%) individuals 
were diagnosed as having hepatic cancer. All the 
suspected cases of HCC were also confirmed on biopsy. 
Mean alpha fetoprotein level in our study was 5322.44 
+2779.82 ng/ml. HCC was more frequent (33.34%) in 
patients with co-infection of chronic hepatitis B and D, as 
compared to patients having only chronic hepatitis B 
(20.80%) but difference was not significant p-value 0.14 
(Table.2). 
 
D i s c u s s i o n  
Hepatic carcinoma is the fifth most frequent cancer and 
3rd common reason of mortality. It is documented that the 
Table 1: Demographic characteristics of 
participants (n=200) 
Characteristics n(%) 
Age groups (years) 
20-40 44(22) 
41-60 134(67) 
>60 22(11) 
Gender   
              Male 142(71) 
Female 58(29) 
Educational status  
Un-educated 114(57) 
          Primary 57(28.5) 
Middle-matric 13(6.5) 
Intermediate 10(05) 
          Graduate 
Socioeconomic status 
06(03) 
 
               lower 113(56.5) 
Middle 70(35) 
Upper 17(08.5) 
Table 2: Association of HCC with HBV & HBV+HDV 
co-infection  (n=200) 
Parameter HCC Total p-value 
With HCC 
n (%) 
Without 
HCC n (%) 
 
  
HBV 36(20.80) 137(88.20) 173  
0.14 
HBV+HDV 09(33.34) 18(66.66) 27 
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hepatitis B virus is one of the commonest oncogenic virus 
in human.10 Prevalence of HCC is high in population 
infected by hepatitis B virus. Additionally, increased risk of 
HCC is reported in HDV infected cases.10 Present study 
has been carried out to determine the proportional 
frequency of HCC in patients affected by chronic hepatitis 
B or chronic co-infection of hepatitis B and hepatitis D. 
The mean age of subjects was 52.83+15.6 years with 
minimum of 20 years and maximum 70 years. Similarly, 
study of   Abbas Z et al10 reported that patient’s mean age 
was 54.6 ± 11.1 years. Another study of Kim HS et al11 
also indicated that mean age was 48 years, with range of 
18 years-94 years and male predominance (64.5%). 
These gender findings are also comparable to our study, 
as out of 200 patients, 142(71%) were male, while 
58(29%) were females. 
In this study, 27(12.5%) subjects were suffering from viral 
hepatitis B and D co-infection. Similarly, a national study 
of Shaikh MA et al12 reported that anti-HDV was positive 
in (23.6%) patients with HBV positive. In some other 
international studies, the sero-prevalence of anti-HDV in 
HBV was reported as 11.5% in Iran and 10.6% in 
India.13,14 In Turkey, the prevalence of anti-HDV 
serological markers were observed as 27.5% in HBV 
related chronic hepatitis.15 
In this current analysis, HCC was more frequent in 
patients with co-infection of chronic hepatitis B and D as 
09(33.34%) out of 27 cases, as compared to only chronic 
hepatitis B patients as 20.80% out of 173 cases. 
Amougou MA et al16 reported that in HCC-cases found, 
hepatitis Delta antibody (Anti-HDV) co-infection was 
present in 41.4 %. Studies had also shown that 
extravagant reproduction of virus particles by HBV in 
combination with HDV leading to massive necro-
inflammation results in HCC.17  
Cases infected by combination of HBV and HDV also 
develop HCC earlier as compared to those having HBV 
infection only.18,19 Saravanan S et al20 researches showed 
the subjects of chronic hepatitis group, suffering from viral 
hepatitis B and are chronically ill, antibodies against 
hepatitis D Virus were present in approximately 5.7% of 
diseased persons. This generally leads to chronic liver 
disease (Cirrhosis) in about 5.9% patients. Co-infection 
including hepatitis D virus is linked to diverse patterns of 
the reciprocal inhibitions of the replication of virus.21  In 
literature it has been reported that HDV suppresses HBV 
replication with most cases being HBeAg -ve and with 
decreased HBV DNA level as compared to cases having 
HBV monoinfection.22-24 Potential mechanisms of virology 
of HBV suppression by HDV as inhibitions of HBV 
enhancers may include proteins of HDV (p24 and p27).25 
Consistently previous studies reported that HBV/HDV co-
infection has higher level of ALT and AST and decreased 
PLT and PTA levels.23,26 As well as patients infected by  
HBV/HDV co-infection are estimated, 1.43 times more 
likely to progress to ESLD (end stage liver disease) as 
compared to those cases having HBV infection only. It is 
suggested that HBV/HDV co-infection leads to more rapid 
progression in hepatic disease as compared to those only 
infected by mono-infection of HBV.16 It is suggested that 
studies should also be conducted in other centers, to find 
out association of HCC with chronic HBV mono-infection 
and chronic co-infection of hepatitis B virus and hepatitis 
D virus and to find out the mechanisms of their 
oncognesis. 
C o n c l u s i o n  
This study accomplished that HCC was more frequent 
amongst patients having co-infection with viral hepatitis D 
as compared to infection of hepatitis B virus alone.  Mono 
infected viral hepatitis B or all HBV infected patients 
should be screened for HDV, because early recognition 
and treatment of co-infected HBV and HDV, may reduce 
the burden of associated morbidity and mortality. 
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